TRCT
JUNS

Tower Research Capital (TRC)’s Jupiter Neurosciences JUNS Stock Holding History

Tower Research Capital (TRC)’s Portfolio JUNS Stock Details JUNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.17K Buy
+384
New +$9.08K ﹤0.01% 4230

Other funds holding JUNS

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.59M AUM 51.04% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.41B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tower Research Capital (TRC)'s JUNS Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Jupiter Neurosciences (JUNS) in Q2 2026: 384 shares worth $6.17K. The stake represents ﹤0.01% of the portfolio and ranks #4230 among its holdings.

11 funds tracked by Wall St. Rank hold JUNS as of Q2 2026.

  • Tower Research Capital (TRC) held 384 shares of Jupiter Neurosciences worth $6.17K as of Q2 2026.
  • Jupiter Neurosciences was a new Tower Research Capital (TRC) position in Q2 2026.
  • Jupiter Neurosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4230 holding.
  • 11 funds tracked by Wall St. Rank held Jupiter Neurosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.